Systematic review comparing the safety and efficacy of conventional and drug‐eluting bead transarterial chemoembolization for inoperable hepatocellular carcinoma
Hepatology Research2014Vol. 45(2), pp. 190–200
Citations Over TimeTop 10% of 2014 papers
Zhibo Xie, Xiaobo Wang, Yuchong Peng, Shao‐Liang Zhu, Liang Ma, Bang‐De Xiang, Wen‐Feng Gong, Jie Chen, Xue‐Mei You, Jinghang Jiang, Le‐Qun Li, Jian‐Hong Zhong
Abstract
Though the available evidence suggests that although DEB-TACE is associated with better tumor response and potentially fewer adverse events, it does not provide greater survival benefit than cTACE. These results need to be validated in high-quality trials with large sample size.
Related Papers
- → Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer?(2018)22 cited
- Clinicopathologic features and risk factors for hepatocellular carcinoma: results from a single center in southern Turkey.(2003)
- Spontaneous rupture of hepatocellular carcinoma.(2002)
- Pathology of hepatocellular carcinoma(2006)
- The medical management of hepatocellular carcinoma (HCC) in Japan: a review with implications for HCC seen in the west.(1997)